Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Eli Lilly has unveiled a new weight loss drug that appears to be delivering the highest weight loss yet in clinical trials ...

Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss ...